PureTech Health (NASDAQ:PRTC) Sees Large Volume Increase

Shares of PureTech Health plc (NASDAQ:PRTCGet Rating) saw unusually-high trading volume on Wednesday . Approximately 968 shares traded hands during mid-day trading, a decline of 21% from the previous session’s volume of 1,227 shares.The stock last traded at $29.20 and had previously closed at $27.72.

Analyst Ratings Changes

Several research firms have issued reports on PRTC. Piper Sandler increased their target price on PureTech Health from $37.00 to $44.00 and gave the stock an “overweight” rating in a research report on Thursday, August 25th. SVB Leerink decreased their price target on shares of PureTech Health from $70.00 to $66.00 and set an “outperform” rating on the stock in a report on Wednesday, June 15th.

PureTech Health Trading Down 6.6 %

The firm’s fifty day moving average price is $27.67 and its two-hundred day moving average price is $25.06. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.54 and a quick ratio of 2.22.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PureTech Health stock. AWM Investment Company Inc. boosted its position in PureTech Health plc (NASDAQ:PRTCGet Rating) by 2,100.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 660,000 shares of the company’s stock after acquiring an additional 630,000 shares during the quarter. AWM Investment Company Inc. owned 2.32% of PureTech Health worth $2,513,000 as of its most recent filing with the Securities & Exchange Commission. 2.32% of the stock is owned by institutional investors.

PureTech Health Company Profile

(Get Rating)

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.

Featured Articles

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.